EGFR inhibitors  

Cetuximab - Erlotinib - Gefitinib - Lapatinib - Osimertinib      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

lung cancer (metastatic)

alectinib
ALEX, 2017alectinibcrizotinibNCT02075840Risk of bias conclusive
YO29449 ongoing alectinibcrizotinibNCT02838420 ongoing
MO29750 ongoing alectinibpremetrexed or docetaxelNCT02604342 ongoing
brigatinib
ALTA-1L ongoing brigatinibcrizotinibNCT02737501 ongoing
ceritinib
ASCEND-4, 2017ceritinibchemotherapyNCT01828099 -
CLDK378A2303 ongoing ceritinibpemetrexed or docetaxelNCT01828112 ongoing
cetuximab
Lynch, 2010cetuximabCTRisk of bias negative
Butts, 2007cetuximabCT alone -
FLEX (Pirker), 2009cetuximab + CTCT aloneNCT00148798suggesting
Rosell, 2008cetuximab + CTCT alone -
crizotinib
Shaw, 2013crizotinibchemotherapyNCT00932893Risk of bias suggesting
PROFILE 1014, 2014crizotinibchemotherapyNCT01154140Risk of bias suggesting
A8081029 ongoing crizotinibchemotherapyNCT01639001Risk of bias ongoing
E4512 ongoing crizotinibplaceboadjuvant NCT02201992Low risk of bias ongoing
erlotinib
OPTIMAL erlotinibPlatinum-based CT EGFR mutations NCT00874419Risk of bias suggesting
EUTRACerlotinibPlatinum-based CT 1st line EGFR mutations NCT00446225Risk of bias suggesting
TITANerlotinibPlatinum-based CT 2nd line NCT00556322Risk of bias negative
TRIBUTE (Herbst)erlotinib + Platinum-based CTPlatinum-based CT 1st line negative
Gatzemeier erlotinib + Platinum-based CTPlatinum-based CT 1st line negative
Mok erlotinib + Platinum-based CTPlatinum-based CT 1st line suggesting
SATURN (Cappuzzo)erlotinib + Platinum-based CTPlatinum-based CT maintenance therapy NCT00556712suggesting
Boutsikouerlotinib + Platinum-based CTPlatinum-based CT 1st line negative
Lee erlotinib + Platinum-based CTPlatinum-based CT 2nd line NCT00550173suggesting
Stinchcombeerlotinib + Platinum-based CTPlatinum-based CTnegative
FASTACT-2 (Wu) erlotinib + Platinum-based CTPlatinum-based CT 1st line NCT00883779suggesting
gefitinib
West Japangefitinib -
Northeast Japangefitinib -
CTONG0806 (Yang), 2013gefitinib -
NEJ002, 2013gefitinibcarboplatin-paclitaxel1L -
Maemondo, 2010gefitinibcarboplatin-paclitaxel2LUMIN-CTR C000000376 -
IPASS (Mok), 2009gefitinibcarboplatin-paclitaxel1LNCT00322452 -
IPASSgefitinibcarboplatin/paclitaxel1L -
WJTOG3405 (Mitsudomi), 2010gefitinibcisplatin plus docetaxel -
WJTOG0203 (Takeda), 2010gefitinibcontinued platinum-doublet chemotherapy -
ISTANA (Lee), 2010gefitinibdocetaxel2Lsuggesting
V-15-32 (Maruyama), 2008gefitinibdocetaxel2Lsuggesting
INTEREST (Kim), 2008gefitinibdocetaxel2Lnegative
SIGN (Cufer), 2006gefitinibdocetaxel2Lnegative
IFCT-0301 study (Morère), 2010gefitinibdocetaxel -
Kris, 2003gefitinibgefitinib2LLow risk of bias -
First Signalgefitinibgemcitabine and cisplatin1L -
INTACT 2, 2004gefitinib paclitaxel and carboplatinpaclitaxel and carboplatin1LLow risk of bias -
NCIC CTG BR19 (Goss), 2013gefitinibplaceboLow risk of bias -
INFORM; C-TONG 0804, 2012gefitinibplaceboNCT00770588 -
EORTC 08021/ILCP 01/03, 2011gefitinibplacebo2LNCT00091156 -
Goss, 2009gefitinibplacebo1L -
SWOG S0023 (Kelly), 2008gefitinibplacebo -
ISEL, 2006gefitinibplacebo2L -
Tsuboi, 2005gefitinibplacebo -
INTACT 1.gefitinib + gemcitabine/cisplatinplacebo + gemcitabine / cisplatin1LLow risk of bias -
INVITE (Crinò), 2008gefitinibvinorelbine1LNCT00256711 -
osimertinib
FLAURA, 2017osimertinibplacebo1LNCT02296125Low risk of bias suggesting
AURA 3, 2017osimertinibplatinum-based therapy plus pemetrexed 2LNCT02151981suggesting